0
0
World Thrombosis Day 2025 emphasizes a comprehensive “from head to toe” approach to blood clot prevention, highlighting the critical links between thrombosis and chronic conditions like cancer, diabetes, and heart disease, with the goal of empowering individuals to take proactive health measures. Thrombosis is responsible for one in four deaths worldwide annually, underlining its status as a major public health priority.
Key Findings and Developments
The 2025 campaign theme, “From Head to Toe, Take Control: Prevent Thrombosis, Protect Your Health,” launched by the International Society on Thrombosis and Haemostasis (ISTH), underscores the systemic nature of blood clots and their connection to major health conditions. Thrombosis, the formation of blood clots in veins or arteries, is the underlying cause of the three leading cardiovascular killers: heart attacks, strokes, and venous thromboembolism (VTE) [edexlive]. VTE, which includes deep vein thrombosis (DVT) and pulmonary embolism (PE), is the third leading cause of vascular death and the most common preventable cause of death in hospitalized patients. Despite this, public awareness remains critically low, with a 2015 global survey showing VTE awareness lagging behind that of heart attack or stroke.
Expert Commentary and Public Health Context
Dr. Pantep Angchaisuksiri, President of the ISTH, emphasized the campaign’s mission to reduce the global burden of blood clots, urging healthcare professionals to assess patient risk, policymakers to support equitable care access, and communities to raise awareness. The campaign has grown significantly since its 2014 inception, now uniting over 7,000 partner organizations in more than 125 countries and reaching an estimated 920 million people through social media. The CDC is also actively involved, funding initiatives to build capacity and increase awareness of VTE, working with advocacy groups to reach patients, providers, and public health officials. This focus is critical, as the CDC notes that VTE is a leading cause of preventable hospital death in the United States, yet fewer than half of at-risk patients receive recommended preventive measures .
Global and National Statistics
The global impact of thrombosis is staggering, with the condition contributing to one in four deaths worldwide each year. In the United States, the burden is equally severe. An estimated 60,000 to 100,000 Americans die from VTE annually, and as many as 900,000 people are affected by the condition each year [cdc]. Hospitalization is a major risk factor, with more than a third of VTE cases linked to a recent hospital stay, and most occurring after discharge [cdc]. The CDC estimates that up to 70% of these healthcare-associated VTEs are preventable [cdc]. The risk is also elevated for specific populations: cancer patients face a five-fold increased risk, and women are five times more likely to experience a VTE during pregnancy, childbirth, or the postpartum period .
Prevention Strategies and Clinical Implications
Preventing VTE hinges on three key strategies: increasing public awareness, conducting VTE risk assessments for hospitalized patients, and ensuring the appropriate use of thromboprophylaxis. Risk assessment models like Caprini, Padua, and IMPROVE help clinicians balance a patient’s clotting risk against their bleeding risk to guide treatment. Preventive measures include pharmacological options, such as anticoagulant medications (e.g., heparin, low-molecular-weight heeparin, or direct oral anticoagulants like apixaban), and mechanical methods, such as compression stockings or pneumatic devices [cdc]. For the general public, simple actions can reduce risk, especially during travel: staying hydrated, avoiding alcohol, moving around every hour, and performing ankle and knee exercises while seated .
Emerging Research and Future Directions
A promising area of research is the development of safer anticoagulants. A new class of drugs targeting factor XI shows potential to prevent clots while minimizing bleeding risk, a major concern with current therapies. A meta-analysis of phase 2 studies found factor XI inhibitors reduced postoperative VTE by 40-50% and clinically relevant bleeding by 59% compared to standard treatment. The results of ongoing trials will determine if these agents can meet this unmet need. The COVID-19 pandemic also highlighted the link between infection and thrombosis, with a study showing the hazard ratio for VTE was 33 times higher in the first week after SARS-CoV-2 infection. However, vaccination was associated with a lower overall risk of thrombosis, underscoring its protective benefit.
Practical Implications for the Public
For health-conscious consumers, the key takeaway is empowerment through knowledge and action. Individuals should be aware of the risk factors for blood clots, which include prolonged immobility, surgery, cancer, pregnancy, obesity, and certain genetic conditions [cdc]. When hospitalized, patients are encouraged to ask their healthcare provider for a VTE risk assessment [heart]. For long-distance travel, adopting simple preventive habits like staying hydrated and moving regularly can significantly reduce risk [heart]. Recognizing the signs of a DVT (swelling, pain, redness in a leg) or a PE (sudden shortness of breath, chest pain, rapid heart rate) is crucial, as sudden death is the first symptom in about 25% of PE cases [cdc]. Taking control “from head to toe” means being proactive about one’s vascular health as part of overall wellness.
Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.
References
